Company
Calliditas Therapeutics AB (publ)
Headquarters: Stockholm, Sweden
Employees: 66
Market Cap
$1.05 Billion
USD as of July 1, 2024
Calliditas Therapeutics AB (publ) Categories
Sweden Healthcare Drug Manufacturers—Specialty & GenericSweden Healthcare Sweden Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.
Financials
| Last Financial Reports Date | Dec. 31, 2016 |
| Revenue TTM | €1.98 B |
| EBITDA | €308.7 M |
| Gross Profit TTM | €1.26 B |
| Profit Margin | 7.00% |
| Operating Margin | 11.43% |
| Quarterly Revenue Growth | 3.30% |
Stocks & Indices
Calliditas Therapeutics AB (publ) has the following listings and related stock indices.
Stock: NASDAQ: CALT wb_incandescent